Huntington's Disease: Can Mice Lead the Way to Treatment?

Mouse models for Huntington's Disease (HD) and HD patients demonstrate motor and behavioral dysfunctions, such as progressive loss of coordination and memory, and share similar transcriptional profiles and striatal neuron atrophy. Clear differences between the mouse and human diseases include almost complete striatal degeneration and rarity of intranuclear inclusions in HD, and the fact that mice expressing full-length mutant huntingtin do not demonstrate a shortened life span characteristic of HD. While no clinical interventions tested in mouse models to date have delayed disease progression, the mouse models provide an invaluable tool for both investigating the underlying pathogenic processes and developing new effective therapies. Inherent differences between humans and mice must be considered in the search for efficacious treatments for HD, but the striking similarities between human HD and mouse models support the view that these models are a biologically relevant system to support the identification and testing of potential clinical therapies.

[1]  J. Mysore,et al.  Factors associated with HD CAG repeat instability in Huntington disease , 2007, Journal of Medical Genetics.

[2]  K. Murphy,et al.  Abnormal cortical synaptic plasticity in a mouse model of Huntington's disease , 2007, Brain Research Bulletin.

[3]  S. Frank Correction:Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study , 2011, BMC Neurology.

[4]  Joseph B. Martin,et al.  Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.

[5]  A. J. Morton,et al.  Use of magnetic resonance imaging for anatomical phenotyping of the R6/2 mouse model of Huntington's disease , 2009, Neurobiology of Disease.

[6]  M. Chesselet,et al.  Mouse models of Huntington's disease. , 2002, Trends in pharmacological sciences.

[7]  Dimitri Krainc,et al.  Transcriptional Repression of PGC-1α by Mutant Huntingtin Leads to Mitochondrial Dysfunction and Neurodegeneration , 2006, Cell.

[8]  G. Bernardi,et al.  Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene , 2001, The European journal of neuroscience.

[9]  He Li,et al.  Mutant Huntingtin Causes Context-Dependent Neurodegeneration in Mice with Huntington's Disease , 2003, The Journal of Neuroscience.

[10]  René Hen,et al.  Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease , 2000, Cell.

[11]  M. Hayden,et al.  Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[12]  S. Tsuji,et al.  CAG repeat disorder models and human neuropathology: similarities and differences , 2007, Acta Neuropathologica.

[13]  Patrik Brundin,et al.  The use of the R6 transgenic mouse models of Huntington’s disease in attempts to develop novel therapeutic strategies , 2005, NeuroRX.

[14]  J. Schiefer,et al.  Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[15]  P. Brundin,et al.  Maintenance of Susceptibility to Neurodegeneration Following Intrastriatal Injections of Quinolinic Acid in a New Transgenic Mouse Model of Huntington's Disease , 2002, Experimental Neurology.

[16]  Steven M Hersch,et al.  Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice , 2005, The Journal of comparative neurology.

[17]  D. Wilkin,et al.  Neuron , 2001, Brain Research.

[18]  M. Hayden,et al.  Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. , 2005, Human molecular genetics.

[19]  Peter S. Harper,et al.  Huntington's disease , 1991 .

[20]  A. Messer,et al.  Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice , 1999, Nature Genetics.

[21]  Yun-Ping Deng,et al.  Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic mice , 2002, The Journal of comparative neurology.

[22]  W. Low,et al.  Age‐Dependent Changes in the Calcium Sensitivity of Striatal Mitochondria in Mouse Models of Huntington's Disease , 2005, Journal of neurochemistry.

[23]  Ole A. Andreassen,et al.  Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease , 2000, The Journal of Neuroscience.

[24]  Michelle K. Lupton,et al.  The Hdh Q150/Q150 knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes , 2007, Brain Research Bulletin.

[25]  Y. Kawaoka,et al.  Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice , 2000, Nature Medicine.

[26]  D. Borchelt,et al.  Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. , 1999, Human molecular genetics.

[27]  He Li,et al.  Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity , 2000, Nature Genetics.

[28]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[29]  M. Chesselet,et al.  Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice , 2008, Neuroscience.

[30]  M. Chesselet,et al.  Early Motor Dysfunction and Striosomal Distribution of Huntingtin Microaggregates in Huntington's Disease Knock-In Mice , 2002, The Journal of Neuroscience.

[31]  Danielle A. Simmons,et al.  Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice , 2009, Proceedings of the National Academy of Sciences.

[32]  D. Borchelt,et al.  Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice , 2004, Experimental Neurology.

[33]  S. Dunnett,et al.  Rule learning, visuospatial function and motor performance in the HdhQ92 knock-in mouse model of Huntington's disease , 2009, Behavioural Brain Research.

[34]  Yu Deng,et al.  Differential Susceptibility to Excitotoxic Stress in YAC128 Mouse Models of Huntington Disease between Initiation and Progression of Disease , 2009, The Journal of Neuroscience.

[35]  J. M. Boutell,et al.  Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. , 1999, Human molecular genetics.

[36]  J. Jankovic,et al.  Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. , 2008, Archives of neurology.

[37]  A. Reiner,et al.  R6/2 neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric mice , 2007, The Journal of comparative neurology.

[38]  J. Palo,et al.  [Huntington's disease]. , 1986, Duodecim; laaketieteellinen aikakauskirja.

[39]  A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease , 2001, Neurology.

[40]  S. Snider,et al.  Controlled clinical trial of cannabidiol in Huntington's disease , 1991, Pharmacology Biochemistry and Behavior.

[41]  M. Hayden,et al.  Cognitive Dysfunction Precedes Neuropathology and Motor Abnormalities in the YAC128 Mouse Model of Huntington's Disease , 2005, The Journal of Neuroscience.

[42]  D. Brooks,et al.  Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease , 1996, Annals of neurology.

[43]  J. Olson,et al.  Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. , 2002, Human molecular genetics.

[44]  S. W. Davies,et al.  Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Xi Chen,et al.  Dopaminergic Signaling and Striatal Neurodegeneration in Huntington's Disease , 2007, The Journal of Neuroscience.

[46]  C. Cepeda,et al.  Changes in Cortical and Striatal Neurons Predict Behavioral and Electrophysiological Abnormalities in a Transgenic Murine Model of Huntington's Disease , 2001, The Journal of Neuroscience.

[47]  Jacki Y. Brown,et al.  Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. , 2006, Human molecular genetics.

[48]  Howard Schulman,et al.  Global changes to the ubiquitin system in Huntington's disease , 2007, Nature.

[49]  A. Morton,et al.  Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice , 2009, Neurobiology of Disease.

[50]  K. Fenger,et al.  Molecular and behavioral analysis of the r6/1 huntington′s disease transgenic mouse , 2003, Neuroscience.

[51]  K. Murphy,et al.  Progressive CAG expansion in the brain of a novel R6/1-89Q mouse model of Huntington's disease with delayed phenotypic onset , 2007, Brain Research Bulletin.

[52]  M. Dragunow,et al.  The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease , 2000, Neuroscience.

[53]  D. Housman,et al.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[54]  R. Myers,et al.  Impaired synaptic plasticity in mice carrying the Huntington's disease mutation. , 1999, Human molecular genetics.

[55]  C. Blakemore,et al.  Dendritic spine pathology and deficits in experience‐dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice , 2004, The European journal of neuroscience.

[56]  C A Ross,et al.  Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. , 2000, Human molecular genetics.

[57]  O. Andreassen,et al.  Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. , 2001, Neurobiology of disease.

[58]  I. Módy,et al.  Pathological Cell-Cell Interactions Elicited by a Neuropathogenic Form of Mutant Huntingtin Contribute to Cortical Pathogenesis in HD Mice , 2005, Neuron.

[59]  Chuan-en Wang,et al.  Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms , 2009, Proceedings of the National Academy of Sciences.

[60]  D. Sengelaub,et al.  Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse , 2008, Neuroscience.

[61]  Cristina Sampaio,et al.  Therapeutic interventions for symptomatic treatment in Huntington's disease. , 2009, The Cochrane database of systematic reviews.

[62]  Colin Blakemore,et al.  Delaying the onset of Huntington's in mice , 2000, Nature.

[63]  J. Schiefer,et al.  The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease , 2004, Brain Research.

[64]  Michael I. Miller,et al.  Longitudinal characterization of brain atrophy of a Huntington's disease mouse model by automated morphological analyses of magnetic resonance images , 2010, NeuroImage.

[65]  Blair R. Leavitt,et al.  Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease , 2005, Experimental Neurology.

[66]  Roger L Albin,et al.  Longitudinal Evaluation of the Hdh (CAG)150 Knock-In Murine Model of Huntington's Disease , 2007, The Journal of Neuroscience.

[67]  J. Olson,et al.  Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. , 2002, Human molecular genetics.

[68]  M. Mcdermott,et al.  A controlled trial of fluoxetine in nondepressed patients with Huntington's disease , 1997, Movement disorders : official journal of the Movement Disorder Society.

[69]  S. Hersch,et al.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease , 2000, Nature Medicine.

[70]  S. Finkbeiner,et al.  Serines 13 and 16 Are Critical Determinants of Full-Length Human Mutant Huntingtin Induced Disease Pathogenesis in HD Mice , 2009, Neuron.

[71]  C. Tanner,et al.  L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia. , 1990, Movement disorders : official journal of the Movement Disorder Society.

[72]  Claire-Anne Gutekunst,et al.  A YAC Mouse Model for Huntington’s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration , 1999, Neuron.

[73]  L. Raymond,et al.  Cleavage at the Caspase-6 Site Is Required for Neuronal Dysfunction and Degeneration Due to Mutant Huntingtin , 2006, Cell.

[74]  M. Beal,et al.  Neuroprotective Effects of Phenylbutyrate in the N171-82Q Transgenic Mouse Model of Huntington's Disease* , 2005, Journal of Biological Chemistry.

[75]  A. Young,et al.  Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1. , 2005, Human molecular genetics.

[76]  J. Olson,et al.  Expression Profiling of Huntington's Disease Models Suggests That Brain-Derived Neurotrophic Factor Depletion Plays a Major Role in Striatal Degeneration , 2007, The Journal of Neuroscience.

[77]  A. Morton,et al.  Selective Discrimination Learning Impairments in Mice Expressing the Human Huntington's Disease Mutation , 1999, The Journal of Neuroscience.

[78]  E. Hirsch,et al.  Neuronal distribution of intranuclear inclusions in Huntington's disease with adult onset , 1998, Neuroreport.

[79]  O. Andreassen,et al.  Creatine Increases Survival and Delays Motor Symptoms in a Transgenic Animal Model of Huntington's Disease , 2001, Neurobiology of Disease.

[80]  Carlos Cepeda,et al.  Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD Mice , 2008, The Journal of Neuroscience.

[81]  Bruce R. Rosen,et al.  Neuroprotective Effects of Creatine and Cyclocreatine in Animal Models of Huntington’s Disease , 1998, The Journal of Neuroscience.

[82]  M. MacDonald,et al.  Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models , 2009, Neurobiology of Disease.

[83]  R. Mott,et al.  Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation , 1997, Nature Genetics.

[84]  R. Albin,et al.  Neuronal intranuclear inclusions and neuropil aggregates in Hdh CAG(150) knockin mice , 2005, Neuroscience.

[85]  F. Pierelli,et al.  The gender effect in juvenile Huntington disease patients of Italian origin , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[86]  L. Ellerby,et al.  Mitochondrial dysfunction in Huntington’s disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice , 2007, Journal of neurochemistry.

[87]  Ruth Luthi-Carter,et al.  Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice , 2003, The Journal of Neuroscience.

[88]  S B Dunnett,et al.  Abnormal Synaptic Plasticity and Impaired Spatial Cognition in Mice Transgenic for Exon 1 of the Human Huntington's Disease Mutation , 2000, The Journal of Neuroscience.

[89]  K. Fenger,et al.  Trinucleotide repeat elongation in the Huntingtin gene in Huntington disease patients from 71 Danish families. , 1993, Human molecular genetics.

[90]  A. Rego,et al.  The R6 lines of transgenic mice: A model for screening new therapies for Huntington's disease , 2009, Brain Research Reviews.

[91]  S. Frank Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators , 2009, BMC neurology.

[92]  C A Ross,et al.  Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity , 2001, Science.

[93]  Huntington's disease transgenic mice are resistant to global cerebral ischemia , 2002, Neuroscience Letters.

[94]  R. Yasuda,et al.  Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. , 2003, Brain : a journal of neurology.

[95]  C. Blakemore,et al.  Impaired learning-dependent cortical plasticity in Huntington's disease transgenic mice , 2004, Neurobiology of Disease.

[96]  M. Mehler,et al.  Impairment of developmental stem cell-mediated striatal neurogenesis and pluripotency genes in a knock-in model of Huntington's disease , 2009, Proceedings of the National Academy of Sciences.

[97]  C. Ross,et al.  Neurobiology of Huntington's Disease , 1996, Neurobiology of Disease.

[98]  G. Rebec,et al.  Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease , 2007, Behavioural Brain Research.

[99]  I. Kanazawa,et al.  Age‐dependent and tissue‐specific CAG repeat instability occurs in mouse knock‐in for a mutant Huntington's disease gene , 2001, Journal of neuroscience research.

[100]  B. Hyman,et al.  Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[101]  Stephen B. Dunnett,et al.  Characterization of Progressive Motor Deficits in Mice Transgenic for the Human Huntington’s Disease Mutation , 1999, The Journal of Neuroscience.

[102]  Dosage effects of riluzole in Huntington’s disease , 2003, Neurology.

[103]  M. MacDonald,et al.  Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. , 2000, Human molecular genetics.

[104]  Jacqueline K. White,et al.  Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. , 1999, Human molecular genetics.

[105]  P. Klivényi,et al.  Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease. , 2010, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[106]  P. Patterson,et al.  Intrabody Gene Therapy Ameliorates Motor, Cognitive, and Neuropathological Symptoms in Multiple Mouse Models of Huntington's Disease , 2009, The Journal of Neuroscience.

[107]  Leslie M Thompson,et al.  Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[108]  Minocycline safety and tolerability in Huntington disease , 2004, Neurology.

[109]  Mauro Delorenzi,et al.  Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. , 2007, Human molecular genetics.

[110]  S. Tavaré,et al.  Analysis of germline mutation spectra at the Huntington's disease locus supports a mitotic mutation mechanism. , 1999, Human molecular genetics.

[111]  S. Hersch,et al.  Neuroprotective Effects of Synaptic Modulation in Huntington's Disease R6/2 Mice , 2007, The Journal of Neuroscience.

[112]  X. Chen,et al.  Tetrabenazine is neuroprotective in Huntington's disease mice , 2010, Molecular Neurodegeneration.

[113]  P. Shelbourne,et al.  Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to cell-specific vulnerability in Huntington's disease? , 2000, Human molecular genetics.

[114]  M. MacDonald,et al.  Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. , 2002, Human molecular genetics.

[115]  J. Gusella,et al.  De novo expansion of a (CAG)n repeat in sporadic Huntington's disease , 1993, Nature genetics.

[116]  Aman A. Savani,et al.  Practice Advisory: Utility of surgical decompression for treatment of diabetic neuropathy: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology , 2007, Neurology.

[117]  仙波 宏史,et al.  症例報告 抗N-methyl-D-aspartate receptor脳炎を発症した成熟囊胞性奇形腫の1例 , 2013 .

[118]  I. Martins,et al.  Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[119]  Giovanni Coppola,et al.  The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice , 2008, Proceedings of the National Academy of Sciences.

[120]  Ole A. Andreassen,et al.  Therapeutic Effects of Coenzyme Q10 and Remacemide in Transgenic Mouse Models of Huntington's Disease , 2002, The Journal of Neuroscience.

[121]  M. Hayden,et al.  A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease , 2008, The Journal of experimental medicine.

[122]  A. Morton,et al.  Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation , 2000, Journal of neurocytology.

[123]  R. Mechoulam,et al.  Cannabidiol reduced the striatal atrophy caused 3‐nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors , 2007, The European journal of neuroscience.

[124]  Dimitri Krainc,et al.  Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease , 2002, Science.

[125]  R. Albin,et al.  Neurological abnormalities in a knock-in mouse model of Huntington's disease. , 2001, Human molecular genetics.

[126]  I. Módy,et al.  Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's disease , 2008, Neuroscience.

[127]  P. Djian,et al.  Protein aggregation in Huntington's disease. , 2002, Biochimie.

[128]  M. MacDonald,et al.  Amyloid Formation by Mutant Huntingtin: Threshold, Progressivity and Recruitment of Normal Polyglutamine Proteins , 1998, Somatic cell and molecular genetics.

[129]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[130]  Elizabeth Evans,et al.  Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. , 2003, Human molecular genetics.

[131]  O. Andreassen,et al.  Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease , 2005, Journal of neurochemistry.

[132]  J. Lucas,et al.  Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain , 2006, The European journal of neuroscience.

[133]  J. Coyle,et al.  Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. , 1976, Nature.

[134]  M. Mcdermott,et al.  A controlled trial of remacemide hydrochloride in Huntington's disease , 1996, Movement disorders : official journal of the Movement Disorder Society.

[135]  G. Bates,et al.  Genetic Knock-Down of HDAC7 Does Not Ameliorate Disease Pathogenesis in the R6/2 Mouse Model of Huntington's Disease , 2009, PloS one.

[136]  S. Augood,et al.  Huntingtin inclusions do not down‐regulate specific genes in the R6/2 Huntington's disease mouse , 2006, The European journal of neuroscience.

[137]  O. Hansson,et al.  Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[138]  M. Chesselet,et al.  Time course of early motor and neuropathological anomalies in a knock‐in mouse model of Huntington's disease with 140 CAG repeats , 2003, The Journal of comparative neurology.

[139]  Scott J Barton,et al.  Altered Information Processing in the Prefrontal Cortex of Huntington's Disease Mouse Models , 2008, The Journal of Neuroscience.

[140]  M. Chesselet,et al.  Decrease in Striatal Enkephalin mRNA in Mouse Models of Huntington’s Disease , 2000, Experimental Neurology.

[141]  J. Coyle,et al.  Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea , 1976, Nature.

[142]  Nicola Pavese,et al.  Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. , 2003, Brain : a journal of neurology.

[143]  M. MacDonald,et al.  Mismatch repair gene Msh2 modifies the timing of early disease in Hdh(Q111) striatum. , 2003, Human molecular genetics.

[144]  C. Blakemore,et al.  Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine , 2005, The European journal of neuroscience.

[145]  P. Holmans,et al.  Brain gene expression correlates with changes in behavior in the R6/1 mouse model of Huntington’s disease , 2008, Genes, brain, and behavior.

[146]  Mark Turmaine,et al.  Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.

[147]  E. Simpson,et al.  Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. , 2003, Human molecular genetics.

[148]  P. Klivényi,et al.  Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease , 2009, Pharmacology Biochemistry and Behavior.

[149]  Carlos Cepeda,et al.  Enhanced sensitivity to N‐methyl‐D‐aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease , 1999, Journal of neuroscience research.

[150]  D. Burns,et al.  Neuroanatomic Profile of Polyglutamine Immunoreactivity inHuntington Disease Brains , 2009, Journal of neuropathology and experimental neurology.

[151]  H. Johnston,et al.  A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. , 1999, Human molecular genetics.

[152]  M. Beal,et al.  Chronic quinolinic acid lesions in rats closely resemble Huntington's disease , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[153]  M. F. Beal,et al.  Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG , 2006, Neurology.

[154]  M. Chesselet,et al.  Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. , 2001, Journal of neurophysiology.

[155]  O. Isacson,et al.  Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients. , 2008, Human molecular genetics.